Stay updated on Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page.

Latest updates to the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedThe ClinicalTrials.gov page now displays the terminated UPGRADE-A study record, including its eligibility criteria, treatment plan, outcomes, and record dates, instead of a 403 Forbidden screen.SummaryDifference48%

- Check21 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check28 days agoChange DetectedA banner announces that NIH is transitioning from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check34 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1; the page remains a 403 error page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study record, indicating restricted access or a server-side issue preventing viewing the trial details. This change affects the user experience by preventing access to the main content on the page.SummaryDifference0.5%

Stay in the know with updates to Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page.